Company news

Arcutis Biotherapeutics, Inc. news in 2021

Arcutis Biotherapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

December 22, 2021

FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

December 21, 2021

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

December 15, 2021

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

December 12, 2021

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

November 3, 2021

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

October 3, 2021

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

September 27, 2021

Arcutis Announces Appointment of Keith Leonard to Board of Directors

September 1, 2021

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

August 24, 2021

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

August 22, 2021

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

Arcutis Announces Additions to its Investor Relations and Communications Team

August 1, 2021

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

July 20, 2021

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

July 11, 2021

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

June 30, 2021

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

June 22, 2021

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

June 8, 2021

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

May 31, 2021

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years

April 11, 2021

Arcutis Announces Updates to its Executive Team

March 25, 2021

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

March 17, 2021

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff

February 17, 2021

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

February 15, 2021

Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock

February 1, 2021

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

January 31, 2021

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

January 19, 2021

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

January 12, 2021

Matthew Moore Joins Arcutis as Chief Business Officer

January 10, 2021

Decks in 2021